Amicus Therapeutics is a biotechnology company focused on the discovering, developing, and delivering medicines for diseases. The company's Commercial Product and Product Candidates include Galafold? (Migalastat HCl), which is for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; Enzyme Replacement Therapy for Pompe disease; and Cyclin-dependent kinase-like 5 (CDKL5) Deficiency Disorder, which is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development.

Appian provides low-code automation platform that accelerates the creation of business applications, enabling its customers to automate their business. The company's platform automates the creation of forms, data flows, records, reports and other software elements that would otherwise need to be manually coded. The company'snSelf-Assembling Interface Layer technology ensures that applications developed on its platform can be deployed across a range of mobile and desktop devices, including desktop web browsers, tablets and mobile phones. The company's platform can be deployed in the cloud or on-premises, with organizations able to access the same functionality and data sources in various cases.

Barings BDC and its wholly-owned subsidiaries are specialty finance companies. The company operates as a closed-end, non-diversified investment company.

Hyster-Yale Materials Handling designs, engineers, manufactures, sells and services a line of lift trucks, attachments and aftermarket parts marketed primarily under the Hyster? and Yale? brand names, to independent Hyster? and Yale? retail dealerships. The company's subsidiary, Zhejiang Maximal Forklift Co., Ltd., is a manufacturer of utility and standard lift trucks and specialized material handling equipment involved in the design, manufacture, service and distribution of Class 1 electric and Class 5 internal combustion engine counterbalance utility and standard platforms, and Class 2 and Class 3 electric warehouse products for both the local China and global markets under the Maximal brand.

Kala Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics using its AMPPLIFY? Mucus Penetrating Particles drug delivery technology, with a focus on the treatment of eye diseases. The company's approved ocular corticosteroid product, INVELTYS? (loteprednol etabonate ophthalmic suspension) is used for the treatment of post-operative inflammation and pain. The company is developing KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The company is evaluating compounds in its receptor Tyrosine Kinase Inhibitor program that inhibit the vascular endothelial growth factor pathway for the treatment of a number of retinal diseases.

Synaptics is a developer and supplier of custom-designed human interface semiconductor product solutions that enable people to interact with a variety of mobile computing, communications, entertainment, and other electronic devices. The company targets the markets for smartphones, tablets, personal computer, products, Internet of Things, products and other select electronic devices, including devices in automobiles. The company's family of products includes: ClearPad?, ClearView?, TouchView?, Natural ID?, TouchPad?, SecurePad?, ClickPad?, ForcePad?, AudioSmart?, VideoSmart?, ImagingSmart?, and other product solutions.